November 9, 2020
Astellas Pharma said on November 6 that it has earned Chinese regulatory approval for its oral androgen receptor signaling inhibitor Xtandi (enzalutamide) for the treatment of adult men with non-metastatic castration-resistant prostate cancer (CRPC) with a high risk of metastasis...read more